NCT06152991View on ClinicalTrials.gov

Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

February 26, 2027

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

GODEX

"The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg"

DRUG

Placebo

"* Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg."

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Celltrion Pharm, Inc.

INDUSTRY

lead

Yoon Jun Kim

OTHER